Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Medpace Holdings, Inc. - Common Stock (NQ:MEDP)

305.66 +9.25 (+3.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Medpace Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Repligen, Bruker, Agilent, Medpace, and Revvity Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides... 
Via StockStory
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
MEDP Q1 Earnings Call: Outperformance Driven by Revenue Upside, Cautious Outlook Amid Funding Uncertainty
Clinical research company Medpace Holdings (NASDAQ:MEDP) announced better-than-expected revenue in Q1 CY2025, with sales up 9.3% year on year to $558.6 million. The company’s full-year revenue guidance... 
Via StockStory
Topics Economy
Exposures Interest Rates
If A Recession Hits, Will Medical Stocks Be A Safe Haven For Investors — Again?
Medical stocks are usually considered defensive. But have they been too hammered by regulatory changes to hold up this year? 
Via Investor's Business Daily
Topics Animal Testing Economy Government
Exposures Animal Testing Economy Political
Insights into Medpace Hldgs's Upcoming Earnings
Via Benzinga
Repligen (RGEN) Q1 Earnings: What To Expect
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be announcing earnings results tomorrow morning. Here’s what to look for. 
Via StockStory
Topics World Trade
Exposures Tariff
MEDP Q1 Earnings Call: Revenue Beats Expectations Amid Cancellations and Industry Headwinds
Clinical research company Medpace Holdings (NASDAQ:MEDP) announced better-than-expected revenue in Q1 CY2025, with sales up 9.3% year on year to $558.6 million. The company’s full-year revenue guidance... 
Via StockStory
Topics Earnings
Exposures Financial
West Pharmaceutical Services Earnings: What To Look For From WST
Healthcare products company West Pharmaceutical Services (NYSE:WST) will be reporting results tomorrow before market open. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Wall Street Bounces Back As Traders Shake Off Powell Jabs
Stocks are higher this afternoon, with all three major indexes bouncing back from Monday’s steep selloff. 
Via Talk Markets
Topics Stocks / Equities
Why Medpace (MEDP) Stock Is Trading Lower Today
Shares of clinical research company Medpace Holdings (NASDAQ:MEDP) fell 11.2% in the pre-market session after the company reported first-quarter 2025 earnings with high expectations heading into the... 
Via StockStory
Medpace Hits 17-Month Low After Bookings Miss Leaves Investors Mystified
The company's bookings missed expectations for the fifth consecutive quarter. Investors are questioning its "path forward." 
Via Investor's Business Daily
Thermo Fisher (TMO) Reports Earnings Tomorrow: What To Expect
Life sciences company Thermo Fisher (NYSE:TMO) will be reporting earnings tomorrow before the bell. Here’s what to expect. 
Via StockStory
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Medpace Holdings Reports Q1 Earnings, Shares Move Lower
Medpace Holdings reports first-quarter financial results after the market close on Monday. Here's a look at the key metrics from the quarter. 
Via Benzinga
Medpace (NASDAQ:MEDP) Beats Expectations in Strong Q1 But Stock Drops
Clinical research company Medpace Holdings (NASDAQ:MEDP) announced better-than-expected revenue in Q1 CY2025, with sales up 9.3% year on year to $558.6 million. The company’s full-year revenue guidance... 
Via StockStory
Earnings Scheduled For April 21, 2025
Via Benzinga
Medpace (MEDP) Q1 Earnings: What To Expect
Clinical research company Medpace Holdings (NASDAQ:MEDP) will be announcing earnings results tomorrow after market close. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
What 5 Analyst Ratings Have To Say About Medpace Hldgs
Via Benzinga
1 Spectacular Growth Stock Down 34% to Buy Hand Over Fist
Via The Motley Fool
Topics Initial Public Offering
Exposures Securities Market
3 Market-Beating Stocks with Solid Fundamentals
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the... 
Via StockStory
1 Healthcare Stock with Solid Fundamentals and 2 to Ignore
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
This Kraft Heinz Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Medpace (NASDAQ:MEDP) and its peers. 
Via StockStory
Drug Development Inputs & Services Stocks Q4 Results: Benchmarking Fortrea (NASDAQ:FTRE)
Let’s dig into the relative performance of Fortrea (NASDAQ:FTRE) and its peers as we unravel the now-completed Q4 drug development inputs & services earnings season. 
Via StockStory
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including Repligen (NASDAQ:RGEN) and... 
Via StockStory
Spotting Winners: Charles River Laboratories (NYSE:CRL) And Drug Development Inputs & Services Stocks In Q4
Looking back on drug development inputs & services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Charles River Laboratories (NYSE:CRL) and its peers. 
Via StockStory
2 Reasons to Watch MEDP and 1 to Stay Cautious
Medpace has been treading water for the past six months, recording a small loss of 4.4% while holding steady at $334.43. The stock also fell short of the S&P 500’s 7.6% gain during that period. 
Via StockStory
Topics Stocks
Exposures US Equities
Why Medpace (MEDP) Shares Are Trading Lower Today
Shares of clinical research company Medpace Holdings (NASDAQ:MEDP) fell 8.7% in the pre-market session after the company reported weak fourth-quarter results: Medpace's full-year revenue, EPS, and... 
Via StockStory
Harmonic Issues Weak Guidance, Joins Fluence Energy, Amkor Technology And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Stay updated with the stocks that are on the move in today's after-hours session.
The regular session of the US market on Monday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
Medpace Stock Falls On Q4 Earnings: The Details
Medpace Holdings Inc (NASDAQ:MEDP) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS